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Abstract 
Background: The impact of left ventricular reverse remodeling (LVRR) on the 
prognosis of Chagas cardiomyopathy is unknown. The aim of this study was to 
determine whether the presence of LVRR can predict mortality in these patients.  
Methods: From January 2000 to December 2010, the medical charts of 159 patients 
were reviewed. LVRR was defined as an increase of left ventricular ejection fraction 
(LVEF) and a decrease of left ventricular end-diastolic diameter (LVDD) by two-
dimensional echocardiography. No patient underwent cardiac resynchronization therapy 
or required mechanical ventricular assistance.  
Results: At baseline, median (25th–75th) LVDD was 64 mm (59–70), and median LVEF 
was 33.2% (26.4–40.1). LVRR was detected in 24.5% of patients in a 40-month (26–
64) median follow-up. In the LVRR group, LVDD decreased from 64mm (59–68) to 60 
mm (56–65; p < 0.001), and LVEF increased from 31.3% (24.1–39.0) to 42.5% (32.2–
47.7; p < 0.001). However, LVRR was not associated with heart failure hospitalization, 
cardiogenic shock, heart transplantation, or mortality (p > 0.05 for all comparisons). 
The Cox proportional hazard model analysis identified only cardiogenic shock (hazard 
ratio [HR]: 2.41; 95% confidence interval [CI]: 1.51–3.85; p < 0.001) and serum sodium 
level (hazard ratio, 0.91; 95% CI: 0.86–0.96; p < 0.001) as independent predictors of 
all-cause mortality.  
Conclusions: Left ventricular reverse remodeling occurs in one quarter of patients with 
Chagas cardiomyopathy and have no impact on the outcome of patients with this 
condition.   
Key words: left ventricular remodeling, heart failure, Chagas cardiomyopathy, 
prognosis; mortality 
 
 
Introduction 
 In the current era, Chagas disease is still a major health problem in Latin 
America, where about 10 million individuals are carriers of the disease, and about 
10,000 people die as result of the disease each year [1]. In view of international 
immigration, Chagas disease has spread throughout the world, and the global costs 
associated with this disease are about 7.2 billion United States Dollars (USD) annually, 
this is higher than that observed in several types of cancer [2]. 
The disease is caused by Trypanosoma cruzi, a protozoan transmitted to humans 
through the feces of a sucking bug. Infection usually occurs in infancy. Approximately 
two decades after infection, about 30% of infected patients develop chronic 
cardiomyopathy and severe complications, as chronic systolic heart failure, and sudden 
cardiac death [3].  
Chronic heart failure (CHF) secondary to Chagas cardiomyopathy (CC), CC has 
a poor prognosis compared to patients with ischemic cardiomyopathy [4], hypertensive 
cardiomyopathy [5], or idiopathic dilated cardiomyopathy [6, 7]. The histopathological 
findings in the chronic stage of CC are focal myocarditis that leads to myocyte loss, 
reparative, and confluent fibrosis throughout the myocardium, ultimately leading to 
geometric changes and ventricular systolic dysfunction i.e., ventricular remodeling [8].  
Left ventricular reverse remodeling (LVRR) is characterized by a decrease of 
left ventricular (LV) dimensions, normalization of LV shape and improvement of 
systolic function [9]. A favorable response to drug therapy with angiotensin converting 
enzyme inhibitors, beta-blockers and aldosterone antagonists has been reported, with 
almost complete reversal of LV dysfunction [10–12]. Although Chagas heart disease 
has been extensive and intensively studied over the past 20 years, a limited number of 
studies have assessed cardiac remodeling quantitatively in long-term follow-up in this 
setting [13, 14]. Male gender and systemic blood pressure seem to be independent 
predictors of cardiac remodeling [15]. 
The ability of treatment for heart failure to decrease left chamber size and to 
improve left ventricular ejection fraction (LVEF) can identify CC patients with a 
modifiable condition and better long-term prognosis. Accordingly, the aim of this study 
was to determine whether LVRR could predict all-cause mortality in patients with CC 
in long-term follow up. 
 
Methods 
Patients selection 
This single-center study retrospectively evaluated the medical charts of patients 
with two positive serologic tests for Chagas disease (hemagglutination and indirect 
immunofluorescence staining) according to the World Health Organization 
recommendation [16]. The clinical diagnosis of heart failure was made by attending 
physicians based on Framingham Criteria for the diagnosis of CHF [17]. After the 
clinical diagnosis of CHF, a two-dimensional (2D) echocardiography was used for each 
patient to confirm the clinical diagnosis, quantify this condition using LVEF, and to 
guide treatment. Individuals with the clinical diagnosis of CHF, secondary to CC and 
LVEF < 55% on first 2D echocardiography confirming LV systolic dysfunction were 
initially screened for this study. Patients with a concomitant disease that could 
potentially cause heart disease by itself were excluded. 
This study was conducted in accordance with the Declaration of Helsinki and 
approved through the local Human Research Ethics Committee of São José do Rio Preto 
Medical School (CAAE — 02716112.6.0000.5415). The need for individual informed 
consent was waived, as this study was a retrospective analysis of prospectively collected 
data for routine care, and breach of privacy or anonymity did not occur. 
 
Data availability 
The data sets generated and/or analyzed during the current study are not publicly 
available due to the use of potentially identifying postal codes in the deprivation 
analysis, as approved by the local Human Research Ethics Committee, but they are 
available upon reasonable request. 
 
Baseline measurements and 2D echocardiographic conditions 
The demographics data, New York Heart Association (NYHA) functional class, 
heart rate, systemic arterial pressure, medical history, standard laboratory tests, 12-lead 
resting electrocardiogram and cardiac electronic implantable devices information were 
obtained upon study entry and retrieved from   the medical chart records.  
Local specialists in 2D echocardiography did the echocardiographic examination 
with patients in the left lateral position. Standard parasternal, apical and subcostal views 
were obtained. Routinely, physicians did place the transducer as far laterally and 
caudally as possible in the apical windows to maximize LV cavity size and avoid 
foreshortening during measures. LVEF was measured by the Simpson method in the 
apical 4-chamber view, which was used for the main analyses, as well as apical 2-
chamber view when possible. Wall motion abnormalities analyses, LV end-systolic 
diameter, left ventricular end-diastolic diameter (LVDD), and right ventricular 
dimension were measured according to the American Society of Echocardiography 
recommendations [18].  
Although there is lack of standardized definitions for reverse remodeling [19], in 
the present investigation, LVRR is defined by the simultaneous presence of the 
following conditions: a) occurrence of an increase of LVEF concomitant with a 
decrease in LVDD; b) this improvement occurred in the absence of cardiac 
resynchronization therapy or mechanical ventricular assistance, as also described by 
Amorim et al. [9]. At the time of the study period, LV volumes were not routinely 
measured. 
 
Prospective follow-up 
The patients were routinely followed from January 02, 2000 to December 30, 
2010 at the Cardiomyopathy Outpatient Service, Hospital de Base, São José do Rio 
Preto Medical School, a public referral center for severe CHF management in the 
northwest of São Paulo, Brazil. The heart failure medical therapy information was 
retrieved from a prospectively collected database of patients. All patients received 
evidence-based treatment for CHF, according to international guidelines at that time. 
Thus, treatment with angiotensin converting enzyme inhibitors or angiotensin receptor 
blocks and beta-blockers at targeted or maximal tolerated doses was considered for all 
patients. Those with pitting edema received furosemide, while those in the NYHA class 
III/IV with a LVEF < 30% were treated with digoxin. Patients usually visited the 
outpatient service every 4 months, and a senior heart failure specialist supervised the 
treatment given. Patients were followed until the study was closed; they were also 
excluded at heart transplantation or death. 
 
Data analysis 
  Data were analyzed using the IBM SPSS Statistical Package v.21 (IBM 
Corporation, Armonk, NY). Variables are presented as absolute numbers and 
percentages and median and interquartile ranges (25th and 75th percentile) when 
applicable. Due to the lack of Gaussian distribution, continuous variables were 
compared using the nonparametric Mann-Whitney test. Chi-square or the Fisher exact 
test was used to compare categorical variables.  
The Cox proportional hazards model was used to evaluate the ability of LVRR 
to independently predict all-cause mortality during long-term follow-up. In the 
multivariable model, variables with a p value < 0.10 in the univariate model, and those 
with known prognostic significance were entered into the backward stepwise approach 
to establish independent predictors of death. The Spearman test was used to establish a 
correlation between continuous variables. The variable which correlated with others and 
with the highest Wald coefficient remained in the model, whereas the other was ruled 
out. Thus, each variable entered the multivariable model in a proportion of at least 10 
events in an attempt to avoid overfitting. The adjusted odds ratio (OR) and 95% 
confidence intervals (95% CI) were calculated for predictors.  
Cumulative survival graphics (Kaplan-Meier) were constructed to demonstrate 
differences in event-free survival (mortality from all-causes). P values of < 0.05 were 
considered statistically significant (two-tailed). 
 
Results 
Potentially two hundred thirty-four patients were screened for taking part in this 
investigation. However, a total of 75 individuals (32%) did not undergo another 
comparative 2D echocardiography during the follow-up because they had died before 
this. Therefore, they were excluded from this investigation. In this context, the study 
evaluated 159 patients (64.2% male) who had a median age of 57 (47–66) years, and 
were followed over a period more than 10 years. The baseline characteristics of the 
patients are shown in Table 1. These individuals were divided into two groups: with and 
without LVRR by echocardiographic evaluations. A similarity (p > 0.05) for all 
variables was observed in the present series. 
The current study population received maximal tolerated daily doses of 
medications, considering samples from drug classes with known prognostic impact in 
ventricular remodeling. LVRR group received mean daily dose (mg/day) of enalapril 
(15.0 ± 5.8), captopril (106.3 ± 49.6), losartan (44.2 ± 11.0), carvedilol (27.6 ± 21.1), 
metoprolol succinate (116.7 ± 58.7), spironolactone (33.3 ± 24.3) and non-LVRR group 
received mean daily dose of enalapril (14.3 ± 8.7; p = 0.357), captopril (75.8 ± 38.0; p = 
0.120), losartan (50.0 ± 24.2; p = 0.789), carvedilol (26.3 ± 17.9; p = 0.860), metoprolol 
succinate (128.1 ± 63.6; p = 0.585), spironolactone (27.5 ± 12.4; p = 0.346), showing no 
difference between groups for optimized therapy, according to guideline 
recommendations during the long-term follow-up. 
Thirty-nine patients (24.5%) with CC presented LVRR during their follow-up. 
Comparing the first and the last 2D echocardiography, this group showed a median of 
3.0 mm (1 to 6 mm) for absolute reduction of LVDD, representing a median of 5.1% 
(1.7 to 10%) reduction. For this group, a median of absolute improvement for LVEF of 
7.0% (4.0 to 11.6%) was also detected, representing around 23.6% (12.7 to 39.7%) of 
improvement. There was a significant difference between this group and the group of 
individuals with LVRR (p < 0.001) for all previous measures. Right ventricle diameter 
and wall motion abnormality did not differ between groups (Table 2).  
Standard laboratory tests, 12-lead resting electrocardiographic findings and 
using cardiac electronic implantable devices observed at study entry were not associated 
with LVRR occurrence. Moreover, patients with LVRR showed no difference for 
hospitalization due to acute decompensated heart failure (59.0%), cardiogenic shock 
(17.9%), and the need to heart transplantation (10.3%) compared to patients without 
LVRR (65.8%, p = 438; 29.2%, p = 0.167; and 8.3%, p = 0.747; respectively). 
The Cox proportional hazards model showed a similar situation for late-
mortality (over period of more than 10 years) between individuals without LVRR 
(54.2%) compared to individuals with LVRR (46.2%, p = 0.384). After adjustment, six 
variables were used in the multivariate model: age (years), gender (male), cardiogenic 
shock, left anterior fascicular block, serum sodium level, and LVRR. Only two 
variables were retained as independent predictors of long-term mortality: cardiogenic 
shock (hazard ratio [HR]: 2.41, 95% CI 1.51–3.85; p < 0.001) and serum sodium level 
(HR: 0.91, 95% CI 0.86–0.96; p < 0.001; Table 3). 
The Kaplan-Meier survival analysis of patients with and without LVRR during 
follow-up is shown in Figure 1. No difference between either group was observed 
regarding survival.  
 
Discussion 
In this study,  LVRR in CC was evaluated as a predictor of long-term mortality. 
According to available research, this is the first study of a cohort of patients with CHF 
secondary to CC evaluating the role of LVRR on outcome in an over 10-year follow-up. 
the present study shows no survival improvement despite of LVRR, thus confirming a 
dismal prognosis and severity of CHF secondary to CC.  
Cardiac reverse remodeling with medical treatment of CHF is well established, 
with demonstrable decreases in LV diameter and improvement in LV function [20–25]. 
It should be noted that, although the volumetric measurements seem to provide the most 
powerful data, LVEF measurements are simpler to obtain and are indeed a marker of the 
remodeling process. As LV volume increases, there is a tendency for a concomitant and 
usually parallel decrease in LVEF, which can be used, itself, as a marker of the 
remodeling process [26]. Interestingly, similar to the results provided by Ramasubbu et 
al. [27] using the echocardiography database from the ESCAPE trial [28], the current 
study demonstrated that changes in these parameters were not associated with outcome 
improvement (long-term mortality) in patients with CC as well. In this context, despite 
LVRR evidenced by improvement in cardiac chamber size and LV function, factors as 
persistent neurohormonal activation, increased oxidative stress, and 
inflammatory/immunological cardiomyocyte damage can be a potential hypothesis to 
explain the present findings [19, 29].  
Only two previous studies which included patients with CC aiming at assessing 
clinical predictors for long-term cardiac remodeling was previously performed in a 
similar cohort. In both studies [13, 15], in contrast to the present results, no significant 
reduction for LVDD was observed during follow-up. It is possible that optimized 
clinical treatment provided to patients in the current study, including targeted or 
maximal tolerated doses of angiotensin converting enzyme inhibitors and 
spironolactone associated to beta-blockers, can account for these discrepant results. 
Moreover, findings herein are similar to those observed in other populations [30, 31].  
The therapeutic agents, mainly angiotensin converting enzyme inhibitors and 
beta-blockers, modify the remodeling process and frequently add other clinically 
relevant benefits in reducing morbidity and mortality in cardiomyopathy patients [32]. 
Several clinical trials using a variety of beta-blockers have demonstrated improvements 
in symptoms, ventricular function, functional capacity, and survival in patients with 
CHF due to ischemic and dilated cardiomyopathies [33–35]. Some studies with beta-
blockers that included patients with CC showed similar benefits [36–40].  
Experimentally, a recent study designed to evaluate the role of carvedilol in the 
context of Chagas disease concluded that the drug did not attenuate cardiac remodeling 
or mortality in a model of CC [41]. This contrasts with other experimental studies in 
which metoprolol was capable in reverting electrocardiographic abnormalities in a rat 
model of Chagas disease, was probably because the reversal of catecholamine toxicity 
in this model [42, 43]. In fact, parasympathetic derangement is believed, along with 
microvascular dysfunction and autoimmunity, to play a central role in the pathogenesis 
of chronic Chagas heart disease [44]. Thus, in the present study, optimized 
pharmacological treatment confirmed its association with LVRR, considering the 
reduction of LVDD and improvement of LVEF, although it has not positively impacted 
on survival. 
Inotropic support and serum sodium level were independent predictors for 
mortality in the current investigation. These findings probably reflect the severity of the 
study population in which about a quarter of individuals showed cardiogenic shock 
during follow-up. Therefore, this may account, at least in part, for the ability of 
inotropic support to predict hyponatremia in patients with CC and, consequently, 
ventricular remodeling [45, 46].  
 
Limitations of the study 
There are some limitations to the present study. This work is a retrospective 
analysis of prospectively collected single-center data and thus, carries the inherent 
disadvantages of retrospective studies. All echocardiographic parameters were not 
available in all patients, and therefore only parameters that had paired measurements (at 
baseline and follow-up) were used in the analysis, resulting in a smaller sample size. 
Unfortunately, LV volumes were not obtained, a finding that could better explain 
LVRR. It must be emphasized that 32% of patients were excluded from the study 
because they had died before undergoing comparative echocardiography. This reflects 
the mortality associated with Chagas disease patients in the real world. Intra- and 
interobserver variability for the echocardiography lab was not mentioned; therefore, it 
was difficult to determine whether the mean changes in parameters fell within the 
measurement variability or reflected true changes. Additionally, multivariate analysis 
included only those factors available in the documented database. Some factors that 
have an effect on prognosis might not have been examined. Thus, present results may 
not be applicable to other specific patient cohorts without further study into the various 
subgroups. Despite these caveats, it should be emphasized that this study was performed 
in a cohort followed at a tertiary referral center for heart failure treatment, where 
patients received the best therapy possible. In addition, the data obtained allowed us to 
perform an ample statistical analysis, which provided its great reliability. Finally, the 
investigation reflects the relentless prognosis of CC in the real world, independent of 
LVRR. 
 
Conclusions 
The present study suggests that LVRR does not predict a reduction in long-term 
all-cause mortality in patients with CC. This is the first study to show that the severity 
of disease progression seems to dissipate the potential benefit of LVRR in patients with 
CC. Further research, however, with larger sample sizes, should be conducted to 
confirm these findings. 
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Table 1. Baseline characteristics of 159 patients analyzed for occurrence of left 
ventricular reverse remodeling (LVRR). 
Baseline 
characteristics 
All patients 
(n = 159) 
LVRR+ (n = 39) LVRR– (n = 120) P 
 
  
Variable     
  Age [years] 57 (47–66) 58 (52–67) 56 (45–65) 0.159 
  Gender (male) 102 (64.2) 23 (59.0) 79 (65.8) 0.438 
  NYHA classes I 
and II 
118 (74.2) 33 (84.6) 85 (70.8) 0.087 
  NYHA classes III 
and IV 
41 (25.8) 6 (15.4) 35 (29.2) 0.087 
  Heart rate 
[beats/min] 
68 (60–78) 68 (60–80) 68 (60–76) 0.681 
  SBP [mmHg] 
110 (100–
120) 
110 (100–120) 110 (100–120) 0.687 
  DBP [mmHg] 70 (60–80) 70 (70–80) 70 (60–80) 0.136 
  Diabetes mellitus 4 (2.5) 2 (5.1) 2 (1.7) 0.252 
Laboratory analysis:     
  Hemoglobin 
[g/dL] 
13.2 (12.0–
14.0) 
13.8 (12.0–14.1) 13.2 (12.0 -14.0) 0.877 
  Sodium [mg/dL] 
141 (138–
144) 
141 (137–144) 141 (138–144) 0.794 
  Potassium [mg/dL] 4.4 (4.1–4.8) 4.4 (3.9–4.8) 4.4 (4.1–4.8) 0.869 
  Creatinine [mg/dL] 1.2 (1.0–1.4) 1.1 (1.0–1.3) 1.2 (1.0–1.4) 0.157 
  CKD-EPI 
[mL/min/1.73 m2] 
63.5 (51.1–
78.6) 
65.3 (52.2–78.6) 63.3 (50.6–79.2) 0.658 
Electrocardiography     
  Atrial fibrillation 41 (25.8) 12 (30.8) 29 (24.2) 0.413 
  ICD 23 (14.5) 6 (15.4) 17 (14.2) 0.851 
  Pacemaker 84 (52.8) 18 (46.2) 66 (55.0) 0.336 
  LBBB 21 (13.2) 3 (7.7) 18 (15.0) 0.242 
  RBBB 63 (39.6) 16 (41.0) 47 (39.2) 0.837 
  LAFB 59 (37.1) 15 (38.5) 44 (36.7) 0.840 
  Low voltage of 
QRS  
9 (5.7) 1 (2.6) 8 (6.7) 0.455 
  VPC 71 (44.7) 19 (48.7) 52 (43.3) 0.557 
Data are shown as median (25th–75th) or number (%). N — number of individuals; NYHA 
— New York Heart Association functional class; SBP — systolic blood pressure; DBP 
— diastolic blood pressure; CKD-EPI — estimated glomerular filtration rate according 
Chronic Kidney Disease Epidemiology Collaboration; ICD — implantable cardioverter-
defibrillator; LBBB — left bundle branch block; RBBB — right bundle branch block; 
LAFB — left anterior fascicular block; VPC — ventricular premature contraction 
 
 
Table 2. Comparison between first and last two-dimensional-echocardiography (2D-
ECHO) during follow-up. 
Baseline 
characteristics 
All patients 
(n = 159) 
LVRR+ (n = 39) LVRR– (n = 120) P 
 
  
First 2D-ECHO:     
  LVDD [mm] 64 (59–70) 64 (59–68) 64 (59–71) 0.605 
  LVSD [mm] 54 (49–60) 56 (50–60) 54 (48–60) 0.440 
  RVD [mm] 23 (19–28) 24 (20–29) 23 (18–28) 0.272 
  WMA 54 (34.0) 12 (30.8) 42 (35.0) 0.628 
  LVEF [%] 
33.2 (26.4–
40.1) 
31.3 (24.1 – 39.0) 33.5 (27.0–40.8) 0.223 
Last 2D-ECHO:     
  LVDD [mm] 65 (60–72) 60 (56–65) 67 (62–74) 
< 
0.001 
  LVSD [mm] 56 (49–63) 49 (42–55) 58 (52–64) 
< 
0.001 
  RVD [mm] 25 (20–33) 27 (22–35) 25 (19–32) 0.485 
  WMA 50 (31.4) 11 (28.2) 39 (32.5) 0.616 
  LVEF [%] 
31.7 (24.8–
41.8) 
42.2 (32.2–47.7) 30.0 (22.7–36.7) 
< 
0.001 
Comparison 
LVDD: 
    
  Absolute 
difference [mm] 
1.0 (–1.0 to 
4.0) 
–3.0 (-6.0 to –1.0) 2.0 (0.0 to 5.0) 
< 
0.001 
  Relative 
difference [%] 
1.4 (–1.8 to 
6.0) 
–5.1 (–10.0 to -1.7) 3.2 (0.0 to 8.1) 
< 
0.001 
Comparison 
LVEF: 
    
  Absolute 
difference [mm] 
0 (–7.8 to 6.4) 7.0 (4.0 to 11.6) –3.1 (–10.6 to 3.2) 
< 
0.001 
  Relative 
difference [mm] 
0 (–23.3 to 
23.6) 
23.6 (12.7 to39.7) –8.4 (–28.8 to 12.0) 
< 
0.001 
Data are shown as median (25th–75th) or number (%). LVRR — left ventricular reverse 
remodeling; N — number of individuals; LVDD — left ventricular end-diastolic 
diameter; LVSD — left ventricular systolic diameter; RVD — right ventricular diameter; 
WMA — wall motion abnormalities; LVEF — left ventricular ejection fraction 
 
 
Table 3. Cox proportional hazard model for independent predictors of long-term 
mortality. 
 Univariate Multivariate 
All patients HR 95% CI P HR 95% CI P 
Age [years] 1.00 0.98–1.01 0.688    
Gender (male) 1.43 0.89–2.30 0.142    
LVRR status 0.76 0.45–1.28 0.303    
Cardiogenic shock 2.49 1.58–3.91 
< 
0.001 
2.41 1.51–3.85 
< 
0.001 
Left anterior fascicular 
block 
1.72 1.12–2.65 0.014    
Serum sodium level 0.91 0.86–0.96 0.001 0.91 0.86–0.96 
 < 
0.001 
HR — hazard ratio; CI — confidence interval; LVRR — left ventricular reverse 
remodeling 
 
 
Figure 1. Kaplan-Meier survival analysis of patients with and without left ventricular 
reverse remodeling considering reduction of left ventricular end-diastolic diameter and 
improvement of left ventricular ejection fraction.  
 

